Provention Bio

$16.60
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.63 (+3.94%) As of 5:43 PM UTC today

Why Robinhood?

You can buy or sell Provention Bio and other stocks, options, and ETFs commission-free!

About PRVB

Provention Bio, Inc. Common Stock, also called Provention Bio, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ. The listed name for PRVB is Provention Bio, Inc. Common Stock.

CEO
Ashleigh W. Palmer
Employees
19
Headquarters
Red Bank, New Jersey
Founded
2016
Market Cap
932.62M
Price-Earnings Ratio
Dividend Yield
Average Volume
630.03K
High Today
$16.68
Low Today
$15.75
Open Price
$16.14
Volume
296.41K
52 Week High
$18.50
52 Week Low
$4.72

Collections

PRVB Earnings

-$0.56
-$0.29
-$0.01
$0.26
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
per share
Actual
Expected Mar 11, Pre-Market

You May Also Like